These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30168968)

  • 41. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
    Durie BG
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
    Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P; Kumar S; Hajek R; Giralt S; Bringhen S; Anderson KC; Richardson PG; Cavo M; Davies F; Bladé J; Einsele H; Dimopoulos MA; Spencer A; Dispenzieri A; Reiman T; Shimizu K; Lee JH; Attal M; Boccadoro M; Mateos M; Chen W; Ludwig H; Joshua D; Chim J; Hungria V; Turesson I; Durie BG; Lonial S;
    Leukemia; 2009 Oct; 23(10):1716-30. PubMed ID: 19494840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [State of the art treatment of progressive or refractory multiple myeloma].
    Schmidt-Wolf IG; Straka C; Scheid C; Einsele H; Goldschmidt H; Engelhardt M
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2091-5. PubMed ID: 25268212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Relapsed/Refractory Multiple Myeloma.
    Neri P; Bahlis NJ; Paba-Prada C; Richardson P
    Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of multiple myeloma with interferon].
    Bruno S
    Medicina (B Aires); 1996; 56 Suppl 1():92-4. PubMed ID: 9224981
    [No Abstract]   [Full Text] [Related]  

  • 47. Therapeutic strategies for the treatment of multiple myeloma.
    Saini N; Mahindra A
    Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment options for myeloma.
    Meenaghan T; Kelly M; Dowling M
    Br J Nurs; 2013 Oct 10-23; 22(18):1084, 1086. PubMed ID: 24121856
    [No Abstract]   [Full Text] [Related]  

  • 49. Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.
    Lonial S
    Mayo Clin Proc; 2007 Mar; 82(3):279-81. PubMed ID: 17352362
    [No Abstract]   [Full Text] [Related]  

  • 50. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Harousseau JL; Moreau P
    N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
    [No Abstract]   [Full Text] [Related]  

  • 51. Palliative Care in Patients With Multiple Myeloma.
    Samala RV; Valent J; Noche N; Lagman R
    J Pain Symptom Manage; 2019 Dec; 58(6):1113-1118. PubMed ID: 31326505
    [No Abstract]   [Full Text] [Related]  

  • 52. The treatment and management of patients who have myeloma.
    King T; Morris M
    Nurs Times; 2004 Jun 22-28; 100(25):30-1. PubMed ID: 15318658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Updates in the treatment of multiple myeloma.
    Berenson JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
    [No Abstract]   [Full Text] [Related]  

  • 54. [Current perspectives in the treatment of multiple myeloma - news and views].
    Knop S
    Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170
    [No Abstract]   [Full Text] [Related]  

  • 55. Myeloma (multiple).
    Kumar A; Djulbegovic B
    Clin Evid; 2006 Jun; (15):1-29. PubMed ID: 16973003
    [No Abstract]   [Full Text] [Related]  

  • 56. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
    Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
    Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An update: health economics of managing multiple myeloma.
    Moeremans K; Annemans L
    Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of multiple myeloma].
    Harousseau JL
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1649-55. PubMed ID: 11103435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trials referral resource. Current clinical trials in multiple myeloma.
    Davis T; Schoenfeldt M
    Oncology (Williston Park); 2004 Feb; 18(2):196-8, 203. PubMed ID: 15008057
    [No Abstract]   [Full Text] [Related]  

  • 60. [Multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2013 Jan; 54(1):89-99. PubMed ID: 23391652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.